← Back to All Filings
DexCom CFO Jereme Sylvain Sells $302.9K in Common Stock Under 10b5-1 Plan
DEXCOM INC
$DXCM4CIK: 0001093557
Subscribe to track DXCM
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📊 DexCom Inc. ($DXCM) Form 4 Filing Insider: Jereme M. Sylvain (EVP, Chief Financial Officer) Transaction: Sold 3,638 shares of Common Stock @ $83.27 Total Value: $302,936.26 Remaining Holdings: 146,828 shares (direct) Notes: Executed pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026.
Comprehensive Analysis
Insider Transaction Overview
- Issuer: DexCom, Inc. ($DXCM)
- Reporting Insider: Jereme M. Sylvain, EVP & Chief Financial Officer
- Filing Date: September 14, 2026
- Transaction Date: September 10, 2026
Transaction Details
- Security: Common Stock
- Transaction Type: Open Market Sale (Code
S) - Shares Sold: 3,638 shares
- Execution Price: $83.27 per share
- Gross Proceeds: $302,936.26
- Post-Transaction Beneficial Ownership: 146,828 shares (includes 87,094 unvested RSUs and 76 shares acquired under the ESPP)
Analysis & Context
- Pre-Arranged Trading Plan (Rule 10b5-1): The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026. This indicates the transaction was scheduled in advance to facilitate orderly personal financial planning rather than driven by real-time non-public information.
- Holding Impact: The transaction represents a small portion (~2.4%) of Mr. Sylvain's total direct equity holdings of 146,828 shares.
- Significance: Low, as the trade is standard executive diversification executed under an established 10b5-1 plan.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.